DE122011100032I1 - Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer. - Google Patents

Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.

Info

Publication number
DE122011100032I1
DE122011100032I1 DE201112100032 DE122011100032C DE122011100032I1 DE 122011100032 I1 DE122011100032 I1 DE 122011100032I1 DE 201112100032 DE201112100032 DE 201112100032 DE 122011100032 C DE122011100032 C DE 122011100032C DE 122011100032 I1 DE122011100032 I1 DE 122011100032I1
Authority
DE
Germany
Prior art keywords
necrosis factor
tumor necrosis
factor alpha
alpha inhibitors
substituted pyridones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE201112100032
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of DE122011100032I1 publication Critical patent/DE122011100032I1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE201112100032 1995-09-19 2011-08-16 Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer. Pending DE122011100032I1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US395595P 1995-09-19 1995-09-19
PCT/US1996/014926 WO1997010712A1 (en) 1995-09-19 1996-09-17 Inhibition of tumor necrosis factor alpha

Publications (1)

Publication Number Publication Date
DE122011100032I1 true DE122011100032I1 (de) 2012-05-16

Family

ID=21708393

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69637050T Expired - Lifetime DE69637050T2 (de) 1995-09-19 1996-09-17 Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer
DE201112100032 Pending DE122011100032I1 (de) 1995-09-19 2011-08-16 Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69637050T Expired - Lifetime DE69637050T2 (de) 1995-09-19 1996-09-17 Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer

Country Status (11)

Country Link
EP (1) EP0866656B1 (de)
JP (1) JPH11512699A (de)
AT (1) ATE360419T1 (de)
AU (1) AU709178B2 (de)
BR (1) BR9610480A (de)
CA (1) CA2232191C (de)
DE (2) DE69637050T2 (de)
MX (1) MX9802150A (de)
TW (1) TW449473B (de)
WO (1) WO1997010712A1 (de)
ZA (1) ZA967880B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
EP1021173A1 (de) * 1997-10-10 2000-07-26 Imperial College Innovations Limited Verwendung von cytokin-unterdrückenden verbindungen (csaid) zur behandlung von gebärmutterkontraktionen
WO1999047140A1 (en) * 1998-03-17 1999-09-23 Margolin Solomon B Topical antiseptic compositions and methods
EP1207870B1 (de) * 1999-08-06 2005-03-16 Innovet Italia S.r.l. N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
AU2001230605A1 (en) * 2000-02-09 2001-08-20 Shionogi And Co., Ltd. Apoptosis inhibitor
WO2002011725A1 (fr) * 2000-08-08 2002-02-14 Shionogi & Co., Ltd. Inhibiteurs de production de cytokine inflammatoire
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
KR100901931B1 (ko) 2002-02-14 2009-06-10 파마시아 코포레이션 Ｐ３８ ｍａｐ 키나제의 조절제로서의 치환된 피리디논
US7067540B2 (en) 2002-02-14 2006-06-27 Pharmacia Corporation Substituted pyridinones
AU2007202607B2 (en) * 2002-02-14 2008-12-18 Pharmacia Corporation Substituted Pyridinones as Modulators of p38 MAP Kinase
EP2987788A1 (de) * 2002-05-17 2016-02-24 Taiwanj Pharmaceuticals Co., Ltd. Opioid und opioidähnliche verbindungen und verwendung davon
SG153727A1 (en) * 2003-02-14 2009-07-29 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
NL1026826C2 (nl) * 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
WO2005047256A1 (fr) * 2003-11-14 2005-05-26 Shanghai Genomics, Inc. Derives de pyridone, et utilisation correspondante
AU2006244072B2 (en) * 2005-05-10 2012-09-20 Intermune, Inc. Pyridone derivatives for modulating stress-activated protein kinase system
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
KR101124070B1 (ko) * 2006-06-05 2012-04-12 제논 파마슈티칼스 인크. 유기 화합물
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP3126362B1 (de) 2014-04-02 2022-01-12 Intermune, Inc. Antifibrotische pyridinone
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
CN111991393A (zh) * 2019-09-26 2020-11-27 深圳先进技术研究院 吡非尼酮在制备防治类风湿性关节炎的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US5518729A (en) * 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5227399A (en) * 1991-02-28 1993-07-13 Merck Frosst Canada, Inc. Pyranylphenyl naphthalene lactones as inhibitors of leukotriene biosynthesis
WO1993007141A1 (en) * 1991-10-11 1993-04-15 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
CA2214531C (en) * 1995-03-03 2009-01-20 Solomon B. Margolin Treatment of cytokine growth factor caused disorders

Also Published As

Publication number Publication date
EP0866656B1 (de) 2007-04-25
TW449473B (en) 2001-08-11
EP0866656A4 (de) 2001-05-23
WO1997010712A1 (en) 1997-03-27
CA2232191A1 (en) 1997-03-27
DE69637050D1 (de) 2007-06-06
MX9802150A (es) 1998-11-30
CA2232191C (en) 2011-03-15
EP0866656A1 (de) 1998-09-30
BR9610480A (pt) 1999-03-16
ZA967880B (en) 1997-04-16
AU7239996A (en) 1997-04-09
JPH11512699A (ja) 1999-11-02
DE69637050T2 (de) 2008-06-19
AU709178B2 (en) 1999-08-26
ATE360419T1 (de) 2007-05-15

Similar Documents

Publication Publication Date Title
DE122011100032I1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
FI925342A0 (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
RS20090086A (en) Nucleoside analogs with carobxamidine modified monocyclic base
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
MY119403A (en) Novel compounds with analgesic effect.
GEP20032954B (en) Heterocyclic Inhibitors of P38
DK0760661T3 (da) Farmaceutiske sammensætninger omfattende en opiat-antagonist og calciumsalte, deres anvendelse til behandling af endorfin-m
ATE252885T1 (de) Plan zur verabreichung von h+, k+-atpase inhibitoren
ATE264107T1 (de) Cyclooxygenaseinhibitor und salze von amidinderivaten, verfahren zu deren herstellung, deren verwendung als arzneiwirkstoffe sowie diese salze enthaltende arzneimittel
DK0837935T3 (da) Den 3'-ikke-translaterede region af det humane prohibitin-gen
NO980215L (no) Nye galantamin-derivater, fremgangsmåte for fremstilling derav, anvendelse derav som legemidler, og farmasöytiske blandinger inneholdende slike derivater
SE9402880D0 (sv) New peptide derivatives
DE69631542D1 (de) Neue geranylgeranylderivate, verfahren zu deren herstellung und entsprechende pharmazeutische zusammensetzungen
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
SE9504662D0 (sv) New compounds
IL126175A (en) Pharmaceutical compositions containing endothelin antagonists and novel endothelin antagonists
AP9200443A0 (en) Heterocyclic compounds.
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
DE69403456D1 (de) Inhibitor gegen kollagenaseaktivität und ihn enthaltende kosmetische zubereitung
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.
MX9701529A (es) Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.
HUP0100188A2 (hu) Aszkorbátot és lizint tartalmazó szinergetikus készítmények extracelluláris mátrixdegeneráció ellen
ATE51149T1 (de) Therapeutische anwendung eines indandionderivats und pharmazeutische zusammensetzungen zu ihrer verwendung.